Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joachim Burman

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
Multiple Sclerosis and Related Disorders|July 11, 2021
Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile?Joachim Burman
Neurology|November 10, 2017
Epilepsy in multiple sclerosis: A nationwide population-based register studyJoachim Burman, Johan Zelano
Journal of Neuroimmunology|March 6, 2016
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosisJoachim Burman, Anders Svenningsson
Neurology|April 30, 2017
Autologous hematopoietic stem cell transplantation for MS: Safer than previously thoughtJoachim Burman, Robert J Fox
Acta Neurologica Scandinavica|July 19, 2022
Temporal trends of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Plos One|June 7, 2017
Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatmentMindaugas Paužuolis, Torsten Eich, Joachim Burman
Multiple Sclerosis and Related Disorders|November 15, 2019
Prognostic impact of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Lakartidningen|November 5, 2020
Ellen Iacobaeus, Joachim Burman, Anne-Marie Landtblom
Brain and Behavior|May 4, 2024
Antibody-positive autoimmune encephalitis and paraneoplastic neurological syndrome: A Swedish case seriesSonja Kosek, Joachim Burman, Anna Rostedt Punga
Epilepsy & Behavior : E&B|May 18, 2021
Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational studyZamzam Mahamud, Samuel Håkansson, Joachim Burman, et al.
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
Multiple Sclerosis and Related Disorders|July 11, 2021
Delaying the inevitable: Are disease modifying drugs for progressive MS worthwhile?Joachim Burman
Neurology|November 10, 2017
Epilepsy in multiple sclerosis: A nationwide population-based register studyJoachim Burman, Johan Zelano
Journal of Neuroimmunology|March 6, 2016
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosisJoachim Burman, Anders Svenningsson
Neurology|April 30, 2017
Autologous hematopoietic stem cell transplantation for MS: Safer than previously thoughtJoachim Burman, Robert J Fox
Acta Neurologica Scandinavica|July 19, 2022
Temporal trends of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Plos One|June 7, 2017
Quantification of γδ T cells and HLA-DR+ NK cells does not predict emergence of new contrast enhancing lesions in MS patients suspending natalizumab treatmentMindaugas Paužuolis, Torsten Eich, Joachim Burman
Multiple Sclerosis and Related Disorders|November 15, 2019
Prognostic impact of epilepsy in multiple sclerosisZamzam Mahamud, Joachim Burman, Johan Zelano
Lakartidningen|November 5, 2020
Ellen Iacobaeus, Joachim Burman, Anne-Marie Landtblom
Brain and Behavior|May 4, 2024
Antibody-positive autoimmune encephalitis and paraneoplastic neurological syndrome: A Swedish case seriesSonja Kosek, Joachim Burman, Anna Rostedt Punga
Epilepsy & Behavior : E&B|May 18, 2021
Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational studyZamzam Mahamud, Samuel Håkansson, Joachim Burman, et al.
Pageof 12